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LIPOPROTEIN(A) (LP[A]) IS A LOW-density lipoprotein (LDL)–like particle synthesized by theliver that consists of an apoli-
poprotein B100 (apo B100)molecule co-
valently linked to a very large glyco-
protein known as apolipoprotein(a)
(apo[a]).1-3 The physiological and vas-
cular effects of the particle remain un-
certain, but Lp(a) has been shown to
enter the arterial intima of humans4;
in vitro and animal studies have re-
ported that Lp(a) can promote throm-
bosis, inflammation, and foam cell for-
mation.5-7
Many prospective epidemiological
studies have reported positive associa-
tions of baseline Lp(a) concentration
with coronary heart disease (CHD)
risk.8-10 A literature-based meta-ana-
lysis of published data from 31 pro-
spective studies reported a relative risk
of 1.5 (95% confidence interval [CI],
1.3-1.6) in a comparison of people in
the top third vs those in the bottom
third of the Lp(a) distribution (corre-
sponding to mean values in these cat-
egories of approximately 50 vs 5
mg/dL).10 However, such reviews8-10
have been insufficiently detailed to en-
able reliable assessment of the nature
of any independent association with
CHD and have not addressed possible
associations with ischemic stroke11 and
nonvascular outcomes. In particular,
Lp(a) concentration is believed to be
correlated with some lipid mark-
ers,12,13 but published studies have not
adjusted for them in a consistent way.
It has been suggested that Lp(a) is as-
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Context Circulating concentration of lipoprotein(a) (Lp[a]), a large glycoprotein at-
tached to a low-density lipoprotein–like particle, may be associated with risk of coro-
nary heart disease (CHD) and stroke.
Objective To assess the relationship of Lp(a) concentration with risk of major vas-
cular and nonvascular outcomes.
StudySelection Long-term prospective studies that recorded Lp(a) concentration and
subsequent major vascular morbidity and/or cause-specific mortality published between
January 1970 and March 2009 were identified through electronic searches of MEDLINE
and other databases, manual searches of reference lists, and discussion with collaborators.
Data Extraction Individual records were provided for each of 126 634 participants
in 36 prospective studies. During 1.3 million person-years of follow-up, 22 076 first-
ever fatal or nonfatal vascular disease outcomes or nonvascular deaths were re-
corded, including 9336 CHD outcomes, 1903 ischemic strokes, 338 hemorrhagic strokes,
751 unclassified strokes, 1091 other vascular deaths, 8114 nonvascular deaths, and
242 deaths of unknown cause. Within-study regression analyses were adjusted for
within-person variation and combined using meta-analysis. Analyses excluded par-
ticipants with known preexisting CHD or stroke at baseline.
Data Synthesis Lipoprotein(a) concentration was weakly correlated with several con-
ventional vascular risk factors and it was highly consistent within individuals over sev-
eral years. Associations of Lp(a) with CHD risk were broadly continuous in shape. In the
24 cohort studies, the rates of CHD in the top and bottom thirds of baseline Lp(a) dis-
tributions, respectively, were 5.6 (95% confidence interval [CI], 5.4-5.9) per 1000 person-
years and 4.4 (95% CI, 4.2-4.6) per 1000 person-years. The risk ratio for CHD, ad-
justed for age and sex only, was 1.16 (95% CI, 1.11-1.22) per 3.5-fold higher usual
Lp(a) concentration (ie, per 1 SD), and it was 1.13 (95% CI, 1.09-1.18) following fur-
ther adjustment for lipids and other conventional risk factors. The corresponding ad-
justed risk ratios were 1.10 (95% CI, 1.02-1.18) for ischemic stroke, 1.01 (95% CI, 0.98-
1.05) for the aggregate of nonvascular mortality, 1.00 (95% CI, 0.97-1.04) for cancer
deaths, and 1.00 (95% CI, 0.95-1.06) for nonvascular deaths other than cancer.
Conclusion Under a wide range of circumstances, there are continuous, indepen-
dent, and modest associations of Lp(a) concentration with risk of CHD and stroke that
appear exclusive to vascular outcomes.
JAMA. 2009;302(4):412-423 www.jama.com
412 JAMA, July 22/29, 2009—Vol 302, No. 4 (Reprinted) ©2009 American Medical Association. All rights reserved.
Downloaded From: http://jama.jamanetwork.com/ by a Imperial College London User  on 08/23/2016
sociated with CHD only at very high
concentrations,14,15 but this sugges-
tion is controversial,16 indicating that
studies with greater power than hith-
erto are needed to characterize the
shape of any dose-response relation-
ship reliably.
The objective of this report is to pro-
duce reliable estimates of associations
of Lp(a) with CHD, stroke, and non-
vascular mortality, incorporating ad-
justment for potential confounding by
risk factors. The present study differs
from previous reports on Lp(a) in sev-
eral importantways that enhance its sci-
entific value and reliability. First, it is
large and comprehensive. Second, har-
monization of individual records al-
lows a consistent approach to adjust-
ment for lipids and other potential
confounders. Third, correction for
within-person variation (regression
dilution)17,18 in Lp(a) concentration and
in potential confounders has beenmade
by use of serial measurements in a sub-
set of participants. Fourth, individual
records are available for each partici-
pant, allowing detailed analyses un-
der different circumstances (such as by
age or at different lipid levels). Fifth,
individuals with known preexisting
CHD and stroke are excluded, limit-
ing any effects of clinically evident dis-
ease on Lp(a) concentration (ie, re-
verse causality). Given the substantial
variations in average Lp(a) levels across
available studies, we emphasize that the
current analyses compare participants
only within each contributing study.
METHODS
Study Design
Details of study selection, data collec-
tion, and harmonization procedures in
the Emerging Risk Factors Collabora-
tion (ERFC) have been described pre-
viously.19 Studies were identified
through electronic searches of data-
bases, scanning of the reference lists of
relevant articles (including previously
published reviews), anddiscussionwith
collaborators of the ERFC (FIGURE 1).
Electronic searches, not limited to the
English language, were performed in
MEDLINE and EMBASE for studies
published between January 1970 and
March 2009 using terms related to
Lp(a) (eg, lipoprotein[a], Lp[a], apo[a],
apolipoprotein[a]) and cardiovascular
disease outcomes (eg, cardiovascular
disease, coronary heart disease,myocar-
dial infarction, stroke).
Studies were considered for inclu-
sion if they had baseline information on
age, sex, Lp(a), and several conven-
tional vascular risk factors; if they did
not select participants on the basis of
having previous cardiovascular dis-
ease; used quantitative Lp(a) assay
methods; recorded cause-specific mor-
tality and/or major vascular morbidity
using accepted criteria; and had ac-
crued more than 1 year of follow-up.
Thirty-six eligible prospective stud-
ies,10,15,16,20-52 including 12 that had not
previously published their findings,*
were included. These studies involved
a total of 126 634 individuals who had
no known prior history of CHD (ie,
myocardial infarction [MI] or angina,
which was defined in each study) or
stroke at the initial (baseline) exami-
nation. The contributing studies com-
prise about 90% of relevant incident
CHD cases identified in known West-
ern studies (TABLE 1); several smaller
studies (collectively comprising about
10% of relevant known incident CHD
cases) could not supply data.53-61 A few
studies62-64 could not be included be-
cause they did not use quantitative as-
say methods.
Concomitant information was avail-
able on Lp(a), age, sex, systolic blood
pressure, smoking habits, history of dia-
betes, body mass index, triglycerides,
and total cholesterol in 106 645 par-
ticipants from 30 studies. A total of
96 113 participants from26 studies had
concomitant data on all the preceding
characteristics plus high-density lipo-
protein (HDL) cholesterol. To mea-
sure Lp(a), 2 studies used in-house as-
says, 32 used commercially available
assays, and 2 did not specify the assay
used. Twenty-one studies used enzyme-
linked immunosorbent assay meth-
ods, 9 immunoturbimetry or neph-
elometry, 3 immunoradiometry, and
1enzyme immunodiffusion (eTable 1;
available at http://www.jama.com).*References 21, 24, 29, 31, 32, 38-42, 47, 50.
Figure 1. Literature Search and Study Selection
36 Studies included in the
meta-analysis
48 Relevant articles or unpublished
studies reviewed
94 Potentially relevant articles
reviewed
2842 Articles identified through 
electronic database search
and hand search of reference
lists of relevant articles
36 Potentially eligible articles
identified
12 Unpublished studies identified
12 Excluded
3 Did not use quantitative methods
to assay Lp(a)
9 Authors were not able to provide data
58 Excluded (did not fulfill inclusion
criteria or duplicate publications)
2748 Excluded based on titles/abstracts
(did not fulfill the inclusion criteria)
Lp(a) indicates lipoprotein(a).
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Twenty-four studies used assays insen-
sitive to apo(a) isoforms.
In registering fatal outcomes, all con-
tributing studies used International
Classification of Diseases coding to at
least 3 digits and ascertainment was
based on death certificates. Twenty-
eight of the 36 contributing studies also
involvedmedical records, autopsy find-
ings, and other supplementary sources
to help classify deaths (eTable 2).
Twenty-nine studies used standard defi-
nitions of MI based on Monitoring
Trends and Determinants in Cardio-
vascular Disease (MONICA) orWorld
Health Organization criteria. Twenty-
five studies reporteddiagnosis of strokes
on the basis of typical clinical features
and characteristic changes on brain
imaging, and most attempted to pro-
vide attribution of stroke subtype.
Table 1. Characteristics of 36 Prospective Studies Contributing Data to the Current Analysis
Sourcea
Participants,
No./Male, No.
Age at
Survey,
Mean
(SD), y
Lp(a), Median
(IQR), mg/dL
Median
Follow-up
(5th-95th
Percentile)
No. of Events
Nonfatal
MI/CHD
Death
CHD
Death
Nonfatal
MI
Fatal
MI
Fatal/Nonfatal Stroke
Non-
CVD
Death
Ische-
mic
Hemor-
rhagic
Unclas-
sified
Cohort Studies
AFTCAPS42c 902/745 59 (7.1) 7.6 (3.3-17.9) 5.7 (4.5-6.8) 21 1 20 1 3 0 0 7
ARIC,20 2001 14 033/6087 54 (5.7) 18.3 (6.9-43.8) 14.1 (5.0-15.7) 850 190 660 114 431 52 16 947
ATTICA21c 1508/777 51 (11.1) 11.4 (4.9-25.2) 5.0 (5.0-5.0) 0 0 0 0 0 0 0 16
BRUN,22 1999 798/385 58 (11.4) 8.8 (4.4-21.6) 15.3 (3.9-15.5) 53 31 22 19 24 14 0 120
CHARL24c 165/165 70 (7.5) 10.4 (3.4-22.3) 6.8 (1.2-7.5) 19 3 16 2 0 2 7 15
CHS 1,23 2003 3860/1480 72 (5.2) 12.6 (4.8-22.2) 12.1 (2.0-12.9) 592 212 380 212 367 62 36 797
COPEN,16 2008 7487/3144 59 (13.6) 19.1 (6.9-42.6) 7.4 (2.4-8.9) 283 36 247 0 184 39 94 525
DUBBO,25 2002 2008/842 68 (6.7) 11.0 (5.0-27.8) 14.1 (1.8-14.9) 273 56 217 0 73 19 81 315
EAS,26 2001 637/323 64 (5.6) 9.2 (3.7-25.4) 15.1 (2.3-15.6) 54 25 29 18 0 2 34 123
FINRISK 92,27 2005 2201/1022 54 (6.2) 12.2 (4.5-31.7) 11.8 (4.4-11.9) 92 21 71 10 45 18 0 114
FRAMOFF,28 1996 2850/1316 54 (9.8) 16.7 (7.1-36.6) 12.0 (5.7-14.4) 109 12 97 0 52 6 0 182
GOH29c 638/307 71 (6.7) 17.5 (10.0-37.0) 3.9 (0.3-6.9) 0 0 0 0 0 0 0 0
GRIPS,30 1997 5784/5784 48 (5.1) 9.0 (4.0-25.0) 9.8 (4.8-10.0) 299 0 299 0 0 0 103 158
KIHD31c 1996/1996 53 (5.3) 9.6 (3.8-22.1) 19.2 (2.9-23.1) 386 11 375 6 104 34 3 239
NHANES 332c 4496/1923 54 (15.7) 23.0 (9.0-46.0) 7.5 (3.9-9.0) 107 107 0 38 0 0 46 321
NPHS II,33 2001 2375/2375 57 (3.4) 10.9 (4.3-29.3) 8.3 (3.5-10.4) 157 18 139 16 28 7 17 97
PRIME,34 2002 7441/7441 55 (2.9) 10.0 (5.0-30.0) 5.2 (5.0-7.3) 115 13 102 10 24 3 3 92
PROCAM,35 1996 3198/2255 43 (10.4) 4.0 (2.0-13.0) 17.4 (5.3-18.6) 94 23 71 8 12 4 2 98
QUEBEC,36 1998 2012/2012 56 (6.9) 19.0 (7.8-47.3) 5.3 (4.3-5.6) 53 5 48 4 0 0 9 45
SHS,37 2002 3837/1515 56 (8.0) 3.0 (1.1-6.7) 12.5 (2.1-14.3) 416 133 283 62 8 8 177 750
TARFS38c 1400/667 54 (10.5) 10.1 (4.2-21.6) 2.2 (1.2-4.5) 3 3 0 3 0 0 3 12
ULSAM39c 1866/1866 51 (4.5) 8.3 (3.4-22.3) 27.1 (5.9-35.8) 485 124 361 60 164 42 30 457
WHITE 240c 7903/5467 49 (6.0) 21.0 (12.0-46.0) 7.6 (3.8-8.2) 170 23 147 18 1 0 3 86
WHS,15 2006 27 791/0 55 (7.1) 10.6 (4.4-32.8) 10.2 (8.4-10.8) 227 10 217 4 229 25 1 540
WOSCOPS,43 2000 4617/4617 55 (5.6) 17.0 (7.0-50.0) 5.0 (2.8-6.0) 299 60 239 0 0 0 61 83
ZUTE41c 305/305 75 (4.5) 12.3 (5.8-28.7) 9.1 (1.1-10.1) 42 13 29 9 1 1 25 65
Subtotal 112 108/54 816 55 (9.5) 12.9 (5.0-32.7) 9.7 (3.6-15.7) 5199 1130 4069 614 1750 338 751 6204
Nested Case-Control Studies (Individually Matched)
BUPA,44 1994 1505/1505 53 (7.2) 19.2 (8.7-47.7) 23.7 (4.5-26.9) 208 208 0 170 0 0 0 173
FIA,45 1998 1492/1073 55 (7.6) 26.5 (11.8-45.0) 3.7 (0.5-8.6) 519 118 401 118 0 0 0 0
FLETCHER,46 2007 689/541 57 (14.3) 20.7 (7.2-59.5) 5.6 (2.2-6.4) 140 NA NA 0 0 0 0 0
HPFS47c 726/726 63 (8.3) 13.0 (5.6-37.3) 7.7 (3.0-8.5) 220 35 185 9 0 0 0 18
MRFIT,48 2001 736/736 47 (5.6) 3.4 (1.2-9.3) 7.1 (6.0-7.8) 246 19 227 13 0 0 0 5
NHS,49 2005 705/0 60 (6.5) 9.5 (4.8-28.2) 8.0 (1.4-8.8) 234 27 207 27 0 0 0 10
Subtotal 5853/4581 55 (9.6) 16.0 (5.5-40.5) 7.0 (1.3-25.9) 1567 407b 1020b 337 0 0 0 206
Nested Case-Control Studies (Frequency-Matched)
BRHS50c 1561/1561 52 (5.3) 6.5 (3.4-16.6) 20.3 (3.7-23.6) 461 169 292 122 0 0 0 221
GOTO 33,51 1993 128/128 51 (0.2) 10.2 (4.2-32.0) 12.8 (1.7-13.1) 16 7 9 4 0 0 0 7
REYK,10 2008 6179/4359 55 (9.0) 9.3 (2.9-22.8) 20.3 (3.3-33.5) 1850 810 1040 228 0 0 0 1476
USPHS,52 1993 805/805 60 (9.0) 9.5 (3.8-24.1) NA 243 22 221 22 153 0 0 0
Subtotal 8673/6853 55 (8.6) 8.7 (3.2-21.8) 20.1 (3.4-32.9) 2570 1008 1562 376 153 0 0 1704
Total 126 634/65 755 55 (9.4) 12.6 (4.9-32.1) 9.8 (3.5-21.3) 9336 2545b 6651b 1327 1903 338 751 8114
Abbreviations: CHD, coronary heart disease; IQR, interquartile range; Lp(a), lipoprotein(a); MI, myocardial infarction; NA, data not available; non-CVD, nonvascular.
aeAppendix 3 lists the study acronyms.
bNumbers sum to less than the total of CHD events because 1 study46 did not provide separate data on CHD death and nonfatal MI.
cStudies that had not previously published their findings on LP(a) and vascular risk.
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Statistical Analyses
Details of the statisticalmethods are pro-
vided in eAppendixes 1 and 2. Normal
distributions were achieved by taking
natural logarithms (loge) of Lp(a). The
pooled standard deviation across stud-
ies in baseline loge Lp(a) concentration
was 1.25, which corresponds to about a
3.5-fold difference (ie, e1.25) on the origi-
nal scale of Lp(a) measurement in mil-
ligrams per deciliter. The primary dis-
ease outcomewasCHD(ie, first-everMI
or fatal CHD), with subsidiary analyses
of stroke by subtype and all cardiovas-
cular deaths.Analyses involved a 2-stage
approach with estimates of association
calculated separately within each study
beforepooling across studiesby random-
effects meta-analysis. Parallel analyses
using fixed-effect models yielded very
similar results (eFigure 1).
Forthe26studiesanalyzedasprospec-
tivecohortstudies,hazardratioswerecal-
culatedusingCoxproportionalhazardre-
gression models stratified by sex (and,
whereappropriate,bystudygroup).The
assumptionsoftheproportionalityofhaz-
ards for loge Lp(a) levels were satisfied.
Eachparticipantcontributedonlyeither
the first nonfatal outcome or death re-
cordedatage20yearsorolder(ie,deaths
precededbynonfatalCHDorstrokewere
not included in the analyses).
For the 10 “nested” case-control stud-
ies within prospective cohorts, odds ra-
tios were calculated using either condi-
tionalorunconditional logistic regression
models, as appropriate.Hazard ratios and
odds ratios were assumed to approxi-
mate the same relative risk and are col-
lectively described as risk ratios (RRs).
To assess the shape of association,
study-specific RRs calculated within
overall quantiles (eg, tenths) of base-
line Lp(a) levelswere combined bymul-
tivariate random-effects meta-analysis
andplottedagainstmeanusual loge Lp(a)
levels within each quantile. Ninety-five
percent CIs were estimated from the
floated variances that reflect the amount
of information underlying each group
(including the reference group).65When
associations were approximately log-
linear, regression coefficients were cal-
culated to estimate the RR associated
with a 3.5-fold (ie, 1-SD) higher Lp(a).
Risk ratios were adjusted progressively
for age, sex, and several other conven-
tional risk factors, with evidence of as-
sociation indicated by the Wald 2 sta-
tistic.66 Heterogeneity between studies
was assessed by the I2 statistic.67,68 (I2 is
a measure of consistency across stud-
ies: the percentage of variance in esti-
mated loge RRs that is attributable to be-
tween study variation as opposed to
sampling variation. Values of I2 close to
0 indicate lack of evidence of heteroge-
neity.) Diversity at the study level (such
as differences by study design or labo-
ratory methods) was investigated by
grouping studies by recorded character-
istics and by meta-regression. Non-
HDL cholesterol (calculated by subtrac-
tion of HDL cholesterol from total
cholesterol) was used as the principal
marker of cholesterol content in proath-
erogenic lipoproteins (eAppendix 2).
Because most characteristics in epi-
demiological studies aremeasuredwith
some error and are subject to fluctua-
tions within individuals over time, cor-
rection for such regression dilution—
ideally, both in levels of Lp(a) and in
potential confounding factors—canhelp
avoid biases that may exaggerate or ob-
scure associations.18,69 Regression dilu-
tion ratios for each characteristic were
calculated by regressing serialmeasure-
ments, taken from participants in the
ERFC, on the established baseline vas-
cular risk factors listed above plus base-
line levels of Lp(a) and duration of fol-
low-up (eAppendix 1).18,69
Correction for within-person varia-
tion in Lp(a) and in potential confound-
ers was achieved by use of conditional
expectations of long-term average (ie,
“usual”) levels of Lp(a) and error-
prone confounders predicted from these
regression calibrationmodels, and used
in assessments of associations with dis-
ease risk, as previously described.70-72
Regression calibration models al-
lowed variability in Lp(a) to vary by its
baseline levels. Analyses were per-
formed using Stata software, release 10
(StataCorp, College Station, Texas), in-
volving 2-sided statistical tests, a sig-
nificance level of P .05, and 95%CIs.
This studywas approved by theCam-
bridgeshire Ethics Review Committee
and was conducted and analyzed inde-
pendently from its funders.
RESULTS
Mean age at entry of participants was
57 (SD, 8) years and 48% were wom-
en; 47%were European and 50%North
American. During 1.3 million person-
years at risk (mean, 10.2 years to first
outcome), there were 9336 CHD out-
comes, 1903 ischemic strokes, 338
hemorrhagic strokes, 751 unclassified
strokes, 1091 other vascular deaths,
8114 nonvascular deaths, and 242
deaths of unknown cause (Table 1).
As expected, mean Lp(a) concentra-
tion varied across studies, but values
were as diverse within groups of stud-
ies that used similar assay methods as
across studies that used differentmeth-
ods (eFigure 2). The overall median of
Lp(a) at baseline was 12.6 (interquar-
tile range, 4.9-32.1) mg/dL. (To con-
vert to µmol/L, multiply by 0.0357.)
Blacks had more than a 100% higher
Lp(a) concentration than whites
(TABLE 2). Racial groups were exam-
ined separately in subanalyses.
Correlates and Within-Person
Variation Over Time
Lp(a) concentration was weakly corre-
lated with several known or suspected
risk factors: positivelywith total andnon-
HDL cholesterol, apo B100, and fibrino-
gen and inversely with loge triglycer-
ides. Lp(a) levels were 12% (95% CI,
8%-16%) higher in women and 11%
(95%CI, 4%-17%) lower in peoplewith
diabetes (Table 2). Repeat information
on Lp(a) was available in 6597 partici-
pants from7 studies (mean interval, 8.3
years) (eFigure 3). The regression dilu-
tion ratio of loge Lp(a), adjusted for age
and sex, was 0.87 (95% CI, 0.81-0.93),
which was considerably higher in these
studies than those for total cholesterol
(0.65; 95%CI, 0.62-0.65), HDL choles-
terol (0.72; 95%CI, 0.70-0.75), loge tri-
glycerides (0.63; 95%CI, 0.61-0.65), or
systolic blood pressure (0.52; 95% CI,
0.49-0.55).
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Associations With CHD
Inanalysesadjusted forageandsexonly,
therewerecontinuousassociationsofLp
(a)withtheriskofCHD,potentiallycon-
sistentwith either a curvilinear or a log-
linear shape (FIGURE2). Statistical tests
of the compatibility of the data with a
linear vs a quadraticmodel suggested a
better fit with a curvilinear shape
(P=.003) (eAppendix 1 and eTable 3).
Inanalysesrestrictedtoparticipantswith
complete informationonrelevantcovar-
iates, theRRforCHDper3.5-foldhigher
Lp(a) level,adjustedforageandsexonly,
was1.16(95%CI,1.11-1.22), and itwas
1.13 (95%CI, 1.09-1.18) following fur-
ther adjustment for systolic bloodpres-
sure, smoking, history of diabetes, and
total cholesterol (TABLE 3). There was
moderate heterogeneity among studies
contributing to the fully adjustedCHD
result (I2=49%; 95% CI, 22%-66%)
(Table 3).
Findingswere broadly similar in sub-
analyses of coronary death and nonfa-
tal MI (FIGURE 3 and eFigure 4), ad-
jus ted for non-HDL and HDL
cholesterol (instead of total choles-
terol) and adjusted for fibrinogen, C-
reactive protein, or apo AI and apo B100
(eTable 4). Because adjustment for total
cholesterolmay obscure associations of
Lp(a) with disease risk because total
cholesterol includes the cholesterol
contained in Lp(a) particles, we con-
ducted sensitivity analyses that cor-
rected also for estimated Lp(a) choles-
terol concentration,73 which gave a
higher RR than without such correc-
tion (eTable 4).
The findings were qualitatively simi-
lar in analyses that excluded the first 5
yearsoffollow-up(eFigure5), ignoredre-
gression dilution (eTable 5), and used
fixed-effectmodels (eFigure1).TheRR,
adjustedforseveralconventionalriskfac-
tors, was 1.27 (95% CI, 1.17-1.38) in a
comparisonof those in the topthirdwith
those in the bottom third of baseline
Lp(a)concentration(eTable5).Intheco-
hort studies, the rates of CHD in the top
and bottom thirds of baseline Lp(a) dis-
tributions,respectively,were5.6(95%CI,
5.4-5.9) per 1000 person-years and 4.4
(95%CI,4.2-4.6)per1000person-years.
TheRRs forCHDdidnot vary impor-
tantly by sex, non-HDL orHDL choles-
terol, triglycerides, blood pressure, dia-
betes, or body mass index (FIGURE 4).
Therewasnoconvincingevidenceofma-
Table 2. Summary of Available Data and Correlates of Lp(a) Levels
Summary of Available Data Correlates of Lp(a)
No. of
Studies
No. of
Participants
Mean (SD)
or %
Pearson Correlation
r (95% CI)a
Percentage Difference (95% CI) in Lp(a)
Levels per 1 SD Higher or Compared
With Reference Category of Correlateb
Loge Lp(a), mg/dLc 36 126 634 2.37 (1.25)
Age at survey, y 36 126 634 57 (8) 0.01 (0.00 to 0.02) 2 (0 to 3)
Sex 36 126 634
Male 34 66 250 52 Reference
Female 21 60 384 48 12 (8 to 16)
Race 26 91 706
White 26 85 046 93 Reference
Black 11 6223 7 119 (84 to 161)
Smoking status 35 122 994
Never/former 35 89 658 73 Reference
Current 34 33 336 27 0 (−2 to 3)
History of diabetes 36 121 027
No 35 113 991 94 Reference
Yes 34 7036 6 −11 (−17 to −4)
Systolic blood pressure, mm Hg 35 120 643 134 (18) 0.01 (−0.01 to 0.02) 1 (0 to 2)
Body mass indexd 35 123 740 26 (5) −0.02 (−0.04 to 0.00) −4 (−6 to −1)
Lipid markers, mg/dL
Total cholesterol 36 126 128 228 (42) 0.12 (0.10 to 0.13) 16 (14 to 18)
HDL-C 33 114 889 49 (15) 0.03 (0.02 to 0.04) 4 (2 to 6)
Non–HDL-C 33 114 876 178 (42) 0.11 (0.09 to 0.13) 14 (12 to 17)
Loge triglyceridesc 35 124 232 4.85 (0.51) −0.05 (−0.07 to −0.02) −6 (−9 to −3)
Apolipoprotein AI 21 91 480 151 (29) 0.02 (0.00 to 0.04) 1 (−1 to 4)
Apolipoprotein B 23 93 058 108 (28) 0.11 (0.09 to 0.13) 15 (11 to 18)
Inflammatory markers
Loge C-reactive protein, mg/Lc 27 78 153 0.62 (1.12) 0.03 (0.01 to 0.05) 4 (2 to 6)
Fibrinogen, mg/dL 25 101 346 326 (78) 0.08 (0.06 to 0.10) 11 (8 to 15)
SI conversions: To convert total cholesterol, HDL-C, and non-HDL-C to mmol/L, multiply by 0.0259; triglycerides to mmol/L, multiply by 0.0113; apolipoproteins to g/L, multiply by 0.01;
C-reactive protein to nmol/L, multiply by 9.524; and fibrinogen to µmol/L, multiply by 0.0294.
Abbreviations: CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; Lp(a), lipoprotein(a).
aPearson correlation coefficients between loge Lp(a) and the row variables, pooled across studies using random-effects meta-analysis.
bPercentage change in Lp(a) levels per 1-SD increase in the row variable (or for categorical variables, the percentage difference in mean Lp[a] levels for the category vs the reference),
adjusted for age and sex and allowing for random effects across studies.
cMedian (interquartile range) values were for Lp(a), 12.6 mg/dL (4.9-32.1 mg/dL); triglycerides, 120 mg/dL (86-173 mg/dL); and C-reactive protein, 1.75 mg/L (0.82-3.87 mg/L).
dBody mass index is calculated as weight in kilograms divided by height in meters squared.
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jor variations in RRs of studies using
isoform-sensitivevs isoform-insensitive
assaysorwithother featuresof studyde-
sign recorded (eFigure 6). Subsidiary
analysesrestrictedtopeopleofEuropean
continental ancestry (90%of thepar-
ticipants) yielded very similar findings
to the overall findings describedherein
(data available from the authors on re-
quest),butcomparisonsofRRsbetween
racial groups lackedpowerbecausedata
were limited on other races/ethnicities
(eFigure 6). In a common set of partici-
pants, theadjustedRRforCHDper1-SD
higherLp(a) concentrationwasconsid-
erably weaker than the corresponding
RRwith non-HDL cholesterol (1.14 vs
1.66, respectively) (eFigure 7).
Associations With Stroke
Inanalysesadjusted forageandsexonly,
theshapeofassociationofLp(a)with the
risk of ischemic stroke was indistinct
(Figure2).Assumingalog-linearassocia-
tion with risk, the age-and-sex-only–
adjustedRRfor ischemicstrokewas1.11
(95%CI, 1.02-1.20) per 3.5-fold higher
usual Lp(a) levels in analyses restricted
toparticipantswithcompleteinformation
onrelevant covariates (Table3).TheRR
was 1.10 (95%CI, 1.02-1.18) following
furtheradjustmentforsystolicbloodpres-
sure, smoking, history of diabetes, and
total cholesterol (Table3).Therewasno
clear evidence of heterogeneity among
studies contributing to ischemic stroke
(I2=30%;,95%CI,0%-64%).Theadjusted
RRs per 3.5-fold higher usual Lp(a) lev-
elswere1.01(95%CI,0.92-1.12) forun-
classified strokeand1.06(95%CI,0.90-
1.26) forhemorrhagic stroke(Figure3).
Associations With
Nonvascular Mortality
The adjusted RR for the aggregate of
nonvascular mortality was 1.01 (95%
CI, 0.98-1.05) (Figure 3). The ad-
justed RRs were 1.00 (95% CI, 0.97-
Figure 2. Risk Ratios for Coronary Heart Disease, Ischemic Stroke, or Nonvascular Death by Quantile of Usual Lp(a) Level
Adjustment for age and sex onlyA
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Lp(a) indicates lipoprotein(a); MI, myocardial infarction. Sizes of data markers are proportional to the inverse of the variance of the risk ratios. Confidence intervals (CIs) were
calculated using a floating absolute risk technique. Studies involving fewer than 10 cases of any outcome were excluded from the analysis of that outcome.
aFurther adjustment for usual levels of systolic blood pressure, smoking status, history of diabetes, body mass index, and total cholesterol. The x- and y-axes are shown on
a log scale. Lowest quantiles are referents.
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1.04) for all cancer deaths and 1.03
(95% CI, 0.97-1.09) for smoking-
related cancer deaths. The adjusted RR
for nonvascular deaths other than can-
cerwas 1.00 (95%CI, 0.95-1.06). There
were too few cases of particular types
of cancer (or other nonvascular out-
comes) to enable reliable analyses by
subtype. Adjusted RRs for major vas-
cular and nonvascular outcomes were
qualitatively similar in analyses that in-
cluded fatal outcomes without censor-
ing previous nonfatal outcomes
(eFigure 8).
COMMENT
Contrary to previous suggestions of
steep threshold effects, the current
analysis of 126 634 individuals has
demonstrated broadly continuous as-
sociations of Lp(a) concentration with
the risk of CHD. Because these asso-
ciations were only slightly reduced af-
ter adjustment for long-term average
levels of lipids andother established risk
factors, it increases the likelihood that
Lp(a) is an independent risk factor for
CHD. Lipoprotein(a) concentration is,
however, a relatively modest coronary
risk factor, being only about one-
quarter as strong overall as non–HDL
cholesterol, although Lp(a) may be-
come proportionallymore important to
CHD at very high concentrations ow-
ing to its potentially curvilinear risk re-
lationship. Because associations of
higher Lp(a) concentration with CHD
are similar at different levels of non-
HDL cholesterol, the absolute benefits
of cholesterol lowering should be
greater if Lp(a) concentration is high
(or when absolute risk is high for some
other reason).
Whereas previous literature-based re-
views of Lp(a) have focused only on
CHD,8-10 the current individual partici-
pant meta-analysis also investigated
stroke subtypes and cause-specificmor-
tality, including nonvascular deaths. Al-
though current data in relation to Lp(a)
concentration and stroke were some-
what sparser and less distinct than those
for CHD, findings were broadly simi-
lar to those for CHD. In contrast, Lp(a)
concentration was unrelated to the ag-
gregate of nonvascular mortality, in-
cluding cancer and noncancer deaths.
Hence, Lp(a) appears to be more spe-
cifically associated with vascular out-
comes than are a number of systemic
markers of inflammation that have been
strongly associated with both vascular
and nonvascular outcomes.66,74,75 As a
subsidiary finding, the current analy-
ses convincingly demonstrate that Lp(a)
concentration ismore consistentwithin
individuals over several years than are
levels of total cholesterol, HDL choles-
terol, or systolic blood pressure.
Recent large studies have reported
highly significant associations of vari-
ants in or near the LPA gene (a locus
known to strongly influence circulat-
ing Lp[a] concentration)76-78 with CHD
risk.79,80 Togetherwith the current find-
ings of continuous, independent, and
specific associations of Lp(a) concen-
tration with vascular outcomes, avail-
able data are consistent with the exis-
tence of a causal relationship and
increase priority for investigation of
Lp(a) as a potential therapeutic target.
Because the current findings show that
Lp(a) concentration is a relativelymod-
est risk factor for CHD, however, in-
terventions capable ofmuchmore pow-
erful and specific Lp(a) lowering than
currently available may be required to
demonstrate any vascular benefits in
randomized trials.
Substantial modification of Lp(a)
concentration has been difficult to
achieve without pharmacological
agents.81 Niacin and certain inhibitors
of cholesteryl ester transfer protein can
reduce Lp(a) by about 20% and about
40%, respectively.82 Contradictory find-
ings have been reported about the effect
of statins on Lp(a) concentration,83,84
and it remains uncertainwhether statin
use attenuates the CHD risk associ-
ated with Lp(a) concentration.2,85,86
Large randomized trials of niacin and
cholesteryl ester transfer protein in-
hibitors in the secondary prevention of
CHDare in progress.87 Such studiesmay
not, however, enable causal infer-
ences because, in addition to Lp(a) low-
ering, these agents increase HDL cho-
lesterol and decrease LDL cholesterol
and triglyceride concentrations. Simi-
lar considerations may apply to mi-
pomersen, an antisense oligonucleo-
tide directed at human apo B100 now in
phase 2 clinical trials that has been
shown to reduce circulating Lp(a) con-
centration by 70% in transgenic mice,
aswell as reducing LDL cholesterol, apo
B100, and oxidized phospholipids.88,89
Table 3. Risk Ratios for Coronary Heart Disease and Ischemic Stroke per 3.5-Fold (1-SD) Higher
Usual Lipoprotein(a) Levels With Progressive Adjustment for Usual Levels of Confoundersa
Adjustments
Risk Ratio
(95%CI) Wald 2
I2, %
(95% CI)
Coronary heart diseaseb
Age and sex only 1.16 (1.11-1.22) 46 57 (36-72)
Age and sex plus
Systolic blood pressure 1.16 (1.11-1.21) 43 57 (36-71)
Smoking status 1.16 (1.11-1.21) 42 57 (36-72)
History of diabetes 1.17 (1.12-1.22) 47 58 (37-72)
Body mass index 1.17 (1.12-1.23) 51 57 (36-71)
Total cholesterol 1.13 (1.09-1.18) 36 49 (22-66)
Ischemic strokec
Age and sex only 1.11 (1.02-1.20) 6 46 (0-72)
Age and sex plus
Systolic blood pressure 1.09 (1.01-1.17) 6 31 (0-64)
Smoking status 1.09 (1.01-1.17) 6 30 (0-64)
History of diabetes 1.10 (1.02-1.17) 7 26 (0-62)
Body mass index 1.10 (1.03-1.18) 8 25 (0-61)
Total cholesterol 1.10 (1.02-1.18) 7 30 (0-64)
Abbreviation: CI, confidence interval.
aAnalyses were restricted to participants with complete information on sex and all confounding variables. Risk ratios
are stratified by sex and study group where appropriate. Studies with fewer than 10 cases of coronary heart disease
or ischemic stroke outcomes were excluded from the analyses of that outcome.
bFor coronary heart disease, 106 645 individuals, 8362 cases, 30 studies.
cFor ischemic stroke, 69 539 individuals, 1684 cases, 13 studies.
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Figure 3. Risk Ratios for Vascular and Nonvascular Outcomes per 3.5-Fold (1-SD) Higher Usual Lp(a) Level, Adjusted for Cardiovascular Risk Factors
1.41.21.00.8
Risk Ratio per 3.5-Fold Higher
Lp(a) Level (95% CI)
No. of
Individuals
No. of
CasesOutcome
No. of
Studies
Risk Ratio
(95% CI)
106 645 8362Nonfatal MI and coronary death 30 1.13 (1.09-1.18)
69 539 1684Ischemic stroke 13 1.10 (1.02-1.18)
48 407 680Unclassified stroke 12 1.01 (0.92-1.12)
56 165 285Hemorrhagic stroke 9 1.06 (0.90-1.26)
102 268 7268Nonvascular death 25 1.01 (0.98-1.05)
72 683 2159Coronary deatha 24 1.14 (1.07-1.22)
91 424 3492All cancer death 20 1.00 (0.97-1.04)
100 378 3745Other nonvascular death 22 1.00 (0.95-1.06)
63 555 1340Smoking-related cancer death 16 1.03 (0.97-1.09)
91 307 2140Other cancer death 19 1.01 (0.94-1.08)
102 221 6045Nonfatal MIa 26 1.12 (1.07-1.18)
Lp(a) indicates lipoprotein(a); MI, myocardial infarction; CI, confidence interval. Sizes of data markers are proportional to the inverse of the variance of the risk ratios.
Risk ratios are adjusted for age, usual levels of systolic blood pressure, smoking status, history of diabetes, body mass index, and total cholesterol and are stratified,
where appropriate, by sex and study group. Studies involving fewer than 10 cases of any outcome were excluded from the analysis of that outcome.
aSubtotals do not add to the total number of coronary heart disease outcomes because some nested case-control studies did not subdivide outcomes into coronary
death or nonfatal MI.
Figure 4. Risk Ratios for Coronary Heart Disease per 3.5-Fold (1-SD) Higher Usual Lp(a) Level, by Age and Thirds of Individual Characteristics
1.41.21.00.8
Risk Ratio per 3.5-Fold Higher
Lp(a) Level (95% CI)
No. of
Individuals
No. of
CasesCharacteristics
No. of
Studies
P Value for
Interaction
Risk Ratio
(95% CI)
.45
.23
.79
.29
.43
.27
.17
.35
.45
Sex
50 016 2197Female 16 1.16 (1.07-1.26)
56 694 6255Male 27 1.13 (1.07-1.19)
History of diabetes
6372 941Yes 27 1.09 (1.01-1.18)
100 212 7495No 28 1.14 (1.09-1.19)
Age at survey, y
74 315 531040-59 26 1.15 (1.09-1.22)
19 359 190060-69 24 1.11 (1.05-1.17)
7939 1010≥70 15 1.07 (0.99-1.15)
Systolic blood pressure, mm Hg
38 682 2212<122 30 1.12 (1.07-1.18)
39 277 2848122-135 30 1.15 (1.08-1.21)
29 653 3413>135 30 1.13 (1.08-1.19)
Body mass indexa
36 098 2338<24 30 1.12 (1.04-1.20)
35 814 288324-27 30 1.13 (1.08-1.18)
35 700 3252>27 30 1.15 (1.08-1.22)
Non–HDL-C, mg/dL
32 834 1307<148 27 1.05 (0.98-1.13)
32 452 1983148-187 27 1.14 (1.06-1.22)
32 438 2816>187 27 1.16 (1.10-1.23)
HDL-C, mg/dL
33 944 2816<43 26 1.15 (1.09-1.21)
32 335 188043-55 26 1.15 (1.08-1.23)
31 321 1389>55 26 1.08 (0.99-1.18)
Triglycerides, mg/dL
35 792 1988<97 29 1.13 (1.07-1.20)
35 220 267897-150 29 1.15 (1.08-1.23)
35 134 3365>150 29 1.14 (1.08-1.19)
Corrected total cholesterol, mg/dLb
35 885 2053<198 30 1.13 (1.07-1.21)
35 870 2757198-235 30 1.17 (1.09-1.25)
35 857 3663>235 30 1.17 (1.11-1.23)
Lp(a) indicates lipoprotein(a); HDL-C, high-density lipoprotein cholesterol; CI, confidence interval. Sizes of data markers are proportional to the inverse of the variance
of the risk ratios. Risk ratios are adjusted for age, usual levels of systolic blood pressure, smoking status, history of diabetes, body mass index, and total cholesterol and
are stratified, where appropriate, by sex and study group. Studies with fewer than 3 cases per stratum were excluded from analyses.
aBody mass index is calculated as weight in kilograms divided by height in meters squared.
bCorrection for the cholesterol content of Lp(a) was made by subtracting estimated Lp(a) cholesterol values from total cholesterol; Lp(a) cholesterol was estimated
from Lp(a) total mass using the following equation: Lp(a)−cholesterol (mg/dL)=0.15Lp(a) (mg/dL)1.24.73
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Even though the first epidemiologi-
cal study of Lp(a) and CHD was re-
ported in1972,90 the investigationof this
lipoprotein as a potential cardiovascu-
lar risk factor has been hampered by the
lack of consistent approaches to itsmea-
surement. International referencemate-
rial for Lp(a) laboratory standardiza-
tion emerged only in 200091 and was
accepted by the World Health Organi-
zation in2003.92 Evenwithmethods that
use the same standard, however, there
is significant variability in measured
Lp(a) concentration if assays are sensi-
tive to variation innumbers of repeat do-
mains in apo(a).93,94 Hence, in 2003 an
expert panel recommended use of as-
say systems not sensitive to apo(a) iso-
forms (eFigure 2B).83 Population differ-
ences can also contribute to variation in
Lp(a) concentration, particularly since
values differ substantially between indi-
viduals andarehighlyheritable.1,78,95Nev-
ertheless, pooled analyses of individual
data fromprospective studies should re-
main informative, provided that, as in the
current study, analyses compare cases
andnoncases onlywithin each studyand
explore potential diversity across groups
of studies using similar assay methods.
Despiteconsiderablescopeforsuchdi-
versity, it isnotable that there is relatively
moderateheterogeneityinRRsamongthe
studies based in 15 different Western
countriescontributingtothecurrentfind-
ings,anobservationthatsupportstheabil-
ity togeneralize thesedata tosuchpopu-
lations.Becausemorethan90%ofthepar-
ticipants in the current study were of
Europeancontinentalancestry,however,
furtherstudiesareneededinnonwhitera-
cialgroups,particularlyinblackandSouth
Asianpopulations,whichhavedifferent
Lp(a)concentrations.96,97TheRRs in the
currentanalysiswerenot stronglydiffer-
entbetweenstudiesusingassayssensitive
and insensitive to apo(a) isoforms (al-
thoughtherewas,ofcourse,somehetero-
geneity within each of these groups of
studies). Although the findings did not
differ appreciably in subgroups defined
bythelaboratoryandpopulationfeatures
recorded, further studiesareneededthat
canexploreingreaterdepthsuchpotential
sourcesofheterogeneityandjointeffects
with other lipid markers. For example,
largestudiesareneededtoassesswhether
Lp(a)particleswithsmaller-sizedapo(a)
isoforms confer even higher RRs for
CHD55,98 (such assessment was not
possible in the current study because it
lacked concomitant data on apo[a] iso-
forms).Similarly,largerstudiesareneeded
toassessproposedsynergy inthepromo-
tionofvasculardiseasethroughoxidative
damage (again, this was not possible in
the current study because the data set
lackedconcomitant informationonoxi-
dized LDL and lipoprotein-associated
phospholipase A2).99-101
CONCLUSION
Under a wide range of circumstances,
there are continuous, independent, and
modest associations of Lp(a) concentra-
tionwith the riskofCHDand stroke that
appear exclusive to vascular outcomes.
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